Galapagos NV Stock Euronext Bruxelles
Equities
GLPG
BE0003818359
Biotechnology & Medical Research
Sales 2024 * | 313M 339M | Sales 2025 * | 302M 327M | Capitalization | 1.72B 1.87B |
---|---|---|---|---|---|
Net income 2024 * | -13M -14.08M | Net income 2025 * | -71M -76.89M | EV / Sales 2024 * | -5.26 x |
Net cash position 2024 * | 3.37B 3.65B | Net cash position 2025 * | 2.97B 3.22B | EV / Sales 2025 * | -4.13 x |
P/E ratio 2024 * |
-44.4
x | P/E ratio 2025 * |
-16.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.64% |
Latest transcript on Galapagos NV
Managers | Title | Age | Since |
---|---|---|---|
Paulus Stoffels
CEO | Chief Executive Officer | 62 | 22-03-31 |
Thad Huston
DFI | Director of Finance/CFO | 54 | 23-05-31 |
Investor Relations Contact | - | 20-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Dickinson
BRD | Director/Board Member | 54 | Mar. 26 |
Jérôme Contamine
BRD | Director/Board Member | 66 | 22-04-25 |
Simon Sturge
BRD | Director/Board Member | 65 | 23-09-18 |
1st Jan change | Capi. | |
---|---|---|
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+44.36% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |